Exousia Bio, Inc. (LMMY) Form 10-Q — Jun 16, 2026
Exousia Bio, Inc. reported zero revenue and a net loss of $50,897 for the nine months ended February 28, 2026. The company disclosed that it has no cash on hand and a working capital deficit of $261,023, leading management to raise substantial doubt about its ability to continue as a going concern. In November 2025, the company completed the acquisition of Exousia AI, a clinical-stage biotechnology firm, and subsequently changed its name from LAMY to Exousia Bio.
Key figures
- Revenue
- 0
- Total Assets
- 22050670
- Cash Position
- 0
- Shares Outstanding
- 73500000
- Rescinded shares
- 21000000
- Convertible note status
- Matured and unpaid
- Convertible note maturity amount
- $250,000
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.